Ongoing Protocols : click on protocol for inclusion-exclusioncriteria (update 1/03/2017)
NON-SMALL CELL LUNG CANCER
The value of surgical mediastinal staging in clinical N1 lung cancer.
Randomized controlled trial comparing the performance of 19 gauge versus 22 gauge EBUS-TBNA needles in lung carcinoma.
Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC.
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.
A Feasibility Trial Evaluating Anti-PD1 Nivolumab Consolidation After Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B NSCLC
A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. (Temporalily on hold)
LDK378 (Ceritinib) (Novartis)
Phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges.
INC280 (Capmatinib) (Novartis)
A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease.
ABEMACICLIB – PEMBROLIZUMAB (Lilly)
A Phase 2 Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV
Non-Small Cell Lung Cancer.
SMALL CELL LUNG CANCER
Hippocampus Avoidance PCI vs PCI
Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial.
A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy.
NINTEDANIB (Boehringer Ingelheim)
Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma.
For further information regarding protocols or clinical trial unit description, please contact the datamanagers: